A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

NCT ID: NCT01909479

Last Updated: 2022-08-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 202 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2018-08-31

Brief Summary

This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult subjects with GHD to assess the safety and efficacy of a long-acting, once weekly injection of modified hGH (MOD-4023).

Conditions

Adult Growth Hormone Deficiency

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

MOD-4023

Group Type: EXPERIMENTAL

MOD-4023

Intervention Type: DRUG

Individualized once weekly dose of MOD-4023

Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Once weekly administration of placebo

Interventions

MOD-4023

Individualized once weekly dose of MOD-4023

Intervention Type: DRUG

Placebo

Once weekly administration of placebo

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Men and women between the age of 23 to 70 years old at screening, inclusive
• GHD subjects as defined in the Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II (2007).
• No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product.
• The IGF-I level at screening ≤-1 SDS of the age and sex normal ranges according to the central laboratory measurements
• Subjects who are on a stable diet and exercise regime and do not have plans to modify their diet or exercise for at least 12 months
• Subject had a DXA screening and the results are interpretable according to the study plan.

Exclusion Criteria

• Women who are pregnant or breast-feeding (at least 6 months delay from childbirth or lactation)
• Evidence of growth benign intracranial tumor within the last 12 months (determined by comparing a previous MRI to a new one obtained no more than 6 months prior to study entry to clarify dynamics of growth).
• History of any cancer. Exceptions to this exclusion criterion include resected in situ carcinoma of the cervix and squamous cell or basal cell carcinoma of the skin with complete local excision. Patients with GHD attributed to treatment of intracranial malignant lesions in childhood or adulthood (or, tumors) or leukemia may also be enrolled into the study provided that a recurrence-free survival period of at least 5 years is well documented in the study record.
• Signs of intracranial hypertension at screening
• Heart insufficiency, NYHA class > 2 (Appendix B)
• History of overt diabetes mellitus (including currently treated, well-controlled DM) defined according to the American Diabetes Association (ADA) Criteriaa. A history of gestational diabetes, resolved after childbirth, is not exclusionary.
• History of Acromegaly

• Minimum Eligible Age: 23 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

OPKO Health, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Opko Biologics

Kiryat Gat, , Israel

Countries

Israel

Other Identifiers

2013-000830-37

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CP-4-005

Identifier Type: -

Identifier Source: org_study_id